Psychedelics
Calgary, Alberta – TheNewswire – July 16, 2021 – MedX (CSE:MXT) (OTC:MXTTF) (CNSX:MXT.CN) reports that it has granted a total of 300,000 medical consultant share purchase options, exercisable for 5 years at $0.18 per share, to three individuals. These options are subject to Regulatory approval. ABOUT MEDXTRACTOR CORP: The Corporation is a Calgary-based company that generates technologically-based solutions. The SHAMAN division is focusing […]
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine Englewood Cliffs NJ, July 12, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with […]
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio
Industry Veteran Dr. Adi Zuloff-Shani Takes The Helm As CEO Toronto, Ontario–(Newsfile Corp. – July 14, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce changes to its […]
PsyBio Therapeutics Announces Uplisting to OTCQB Venture Market
OXFORD, Ohio and COCONUT CREEK, Fla., July 14, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health challenges and other disorders, is pleased to announce that its […]
Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol “SILFF”
TORONTO, July 13, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“ Silo Wellness ” or the “ Company ”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, announces that its common shares are now trading on the OTCQB® Venture Market under the symbol “SILFF”. The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international […]
Calgary, Alberta – July 13, 2021. For Immediate Release – Medxtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) reports filing of a patent application at the United States Patent and Trademark Office (USPTO). MedX (CSE: MXT, OTC:MXTTF) reports that it has been notified by it’s patent agent that U.S. Patent Application No. 63/220,004, METHOD […]
Wesana Health Announces Definitive Agreement to Acquire PsyTech Inc.
PsyTech Inc, including the psychiatric therapeutic SaaS platform Tovana Solutions and psychiatric clinical network Tovana Clinics, to become wholly owned subsidiary of the emerging life sciences company CHICAGO and TORONTO, July 13, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging life sciences company focused on developing innovative approaches […]
Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol “SILFF”
TORONTO, July 13, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, announces that its common shares are now trading on the OTCQB® Venture Market under the symbol “SILFF”. The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international […]
Optimi Health Joins First Psychedelic Exchange Traded Fund
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund (“ETF”) (NEO: PSYK). The ETF began trading on the Neo Exchange as of […]
The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine. VANCOUVER, BC, July 13, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, announces […]
Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy. The company is evolving its programs beyond the psychedelic molecule, into an eco-system that may potentially drive […]
Calgary, Alberta – TheNewswire – July 13, 2021 – MedX (CSE:MXT), (CNSX:MXT.CN), (OTC:MXTTF) reports that it has been notified by it’s patent agent that U.S. Patent Application No. 63/220,004, METHOD OF GENERATING CREDIBLE SOLUTIONS FROM NON-VALIDATED DATASETS, in the name of Medxtractor Corp., has been filed with the USPTO. This application relates to the previously-filed provisional patent filed in late December, 2020 and assigned […]
Ehave to provide data integrity and patient privacy while allowing patients to share their medical data with medical providers and research organizations MIAMI, July 13, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced a partnership with Health Wizz, a […]
MedXtractor’s Reference Database Sets the Stage for SHAMAN & YMI
Artificial intelligence is already transforming many parts of our everyday lives. For example, Netflix recommends movies we’d enjoy, Facebook identifies friends in photos, and Alexa understands voice commands. Yet, despite these recent advances, most experts agree that AI is only starting to scratch the surface of what’s possible. According to Grand View Research, the global […]
BetterLife Provides H1 2021 Progress Update
VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, announces significant progress in H1 2021. TD-0148A BetterLife’s TD-0148A is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that has been synthesized […]
Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disorders and will provide data on a regulated model for MDMA-assisted therapy VANCOUVER, BC, July 12, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased […]
Ketamine One Aims to Become a North American Mental Health Leader
Nearly one in five Americans were living with a mental illness or addiction in 2019, according to the National Institutes of Health. While the U.S. spends $16 billion on mental health treatments and ancillary services each year, challenges connecting with patients, significant adverse side effects, and other factors have made the problem difficult to overcome. […]
Atai Life Sciences N.V. Added to the North American Psychedelics Index
TORONTO, July 8, 2021 /CNW/ – Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) is announcing that Atai Life Sciences N.V. (“Atai Life Sciences“) has been included as a fast entry addition to the North American Psychedelics Index, (the “Index“), which is the underlying index of the Horizons Psychedelic Stock Index ETF (“PSYK“:NEO). The Index is designed to provide […]
Calgary, Alberta – July 9, 2021. Medxtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) reports share sales by its majority shareholder. MedX (CSE: MXT, OTC:MXTTF) reports that it has been notified by it’s President and controlling shareholder James Durward, that he has sold, pursuant to a Form 45-102F1 Notice of Intention to Distribute Securities […]
Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval NAPLES, Fla., July 8, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that the Company has received approval from the Israeli Ministry of Health to begin […]
Enveric Bio’s Acquisition of MagicMed Accentuates Strengths of Each Company
When two companies merge, or one is acquired by another, the reasoning behind the deal often falls into one of two categories. Either the companies are competitors with the merged entity grabbing a larger portion of their shared market, or they are complementary and perhaps working in adjacent fields. In either case, the strengths […]
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“ Ketamine One ” or the “ Company ”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its Board of Directors (the “ Board ”) has appointed Adam Deffett as […]
TORONTO, July 07, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that its first lead clinical candidate, MSP-1014, a differentiated next-generation psilocybin drug […]
Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide
Englewood Cliffs NJ, July 07, 2021 (GLOBE NEWSWIRE) — Silo and University of Maryland, Baltimore extend Option agreement Rheumatoid arthritis (RA) is a chronic disease in which autoimmune attack leads to joint inflammation, deformities and disability Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has extended its exclusive […]
Dr. Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid July 06, 2021 08:30 ET | Source: Ehave MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital […]
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has signed a Memorandum of Understanding (MoU) with South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London, aimed at advancing psychedelic […]
Toronto, Ontario–(Newsfile Corp. – July 2, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that it has retained Edge Growth Holdings Corporation (“Edge Communications Group” or “Edge“) for […]
MedXtractor Fills a Key Gap in Mental Health Treatments
According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. MedXtractor Corp.’s (CSE: MXT) (OTC: […]
Toronto, Ontario–(Newsfile Corp. – June 30, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that (further to its press releases of May 27, 2021, and June 20, 2021) […]
Ehave Looks to Power the Psychedelics Revolution
Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days lost due to these conditions each year. Conventional therapies have a mixed track record, but psychedelics have shown much promise in recent years. The challenge for researchers and medical professionals is […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
CannaTrac® is dedicated to bringing safety to the cannabis industry by serving as the industry’s leading cashless mobile payment system solution. CannaTrac® created the CannaCard® and the CannaCard App™ to provide consumers and retailers with a convenient way to benefit from increased safety and convenience through cashless purchases within the legal cannabis industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
